ECGR Bellatora Inc (PK)

Oncology Med, Inc. (PINKSHEETS: ONCO), a Pittsburgh based cancer treatment solutions group, announced today that it has begun providing prostate cancer brachytherapy treatment services under a new multiple year exclusive contract with Southwestern Ambulatory Surgery Center; a physician owned surgery center being managed by Titan Healthcare, one of the largest surgery center management companies in the United States. This exclusive multi-year contract will have Oncology Med providing physics and full turnkey prostate cancer brachytherapy services, equipment, staff, and radionuclide seed management to the surgery center and affiliated radiation oncologists.

According to William Walker, Ph.D., Oncology Med's CEO and founder, "We are continuing to expand our footprint in the treatment of prostate cancer in the ambulatory surgery center market because it is customer friendly to the patients and physicians, a very viable and excepted treatment for the cure of prostate cancer, has a lower cost to the healthcare market than traditional hospital programs, and is a solid revenue generator for our company. We will continue to aggressively seek out new clients and contracted sites for our turnkey prostate cancer program for the simple reason that it is a win/win for everyone; the patients who seek minimally invasive cures for their cancer and ASCs who seek low cost healthcare programs with good revenue margins."

"We are proud of our progress in securing new ambulatory surgery center programs as well as hospital based cancer treatment programs for low dose (LDR) and high dose (HDR) radiation treatment for prostate and breast cancer, " added Jack Sloan, Vice President of Business Development. "Not only are they great revenue sources for our company, but these programs give us great pride in that we are able to provide such a high quality of healthcare services for patients through our contracted facilities to enable them a minimally invasive, curative treatment for their cancers with a lower cost of delivery."

LDR, or low dose radiation, treatment for prostate cancer is the minimally invasive insertion of small radioactive seeds into the prostate for the treatment of prostate cancer. The patient spends a limited time in an outpatient setting, generally 3-5 hrs, and is sent home the same day after treatment. In some cases, the patient may receive some additional external beam radiation for 3-5 weeks thereafter on an outpatient basis to ensure that all cancerous areas including marginal areas around the prostate have been thoroughly treated to eradicate the cancer.

"Our ambulatory surgery center (ASC) prostate brachytherapy programs have been both clinically and financially successful for Oncology Med mainly due to our speed of implementation after contract execution and clinically excellent services provided to the surgery centers and physicians," Sloan continued.

"In addition to our LDR and HDR clinical programs, our consultation services for initiation of new programs and particularly in the area of securing new and amended radiation licenses relieves our contracted facilities of the headaches of dealing with these issues alone," Walker added. "In this new era of Nuclear Regulatory Commission (NRC) regulation changes and those states which have expanded their own regulatory programs, having a partner like Oncology Med who is on top of all the regulatory issues assisting with making this a smooth process for obtaining or expanding a radiation license is crucial," he concluded.

Oncology Med continues to expand and provide extensive consultation services for new and expanded cancer center construction, certification, and credentialing processes for Joint Commission, as well as complete turnkey programs for continuation or implementation of radiation treatment programs for ambulatory surgery centers, radiation oncologists, urologists, and hospitals.

All inquiries for Oncology Med's programs and services should be made to its administrative offices at: Oncology Med, Inc., 11928 Ropp Lane, Lovettsville, VA 20180. Phone: (540) 822-5161

About Oncology Med, Inc.

Oncology Med is a public company engaged in the fulfillment of services related to the treatment of various cancers. It currently provides analysis and design of radiation treatment plans in order for radiation oncologists to administer radiation treatments to cancer patients. Current services facilitate radiation treatment programs ranging from external beam radiation to more advanced radiation treatment technologies.

More information about Oncology Med, Inc. can be found at www.oncologymed.com.

NOTE: This press release may contain "forward-looking statements." In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "potential," "continue" or the negative of such terms and other comparable terminology. These forward-looking statements include, without limitation, statements about our market opportunity, our strategies, competition, expected activities and expenditures as we pursue our business plan, and the adequacy of our available cash resources. Although we believe that the expectations reflected in any forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Actual results may differ materially from the predictions discussed in these forward-looking statements. Changes in the circumstances upon which we base our predictions and/or forward-looking statements could materially affect our actual results.

For information, please contact: Oncology Med, Inc. (540) 822-5161 Email Contact